# US 2022/0008527 A1 · Heat Shock Protein-Binding Peptide Compositions And Methods Of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008527 A1
- Document ID: US20220008527A1
- Status: Published application
- Kind: A1
- Application number: 17/350,723
- Filed: 2021-06-17
- Published: 2022-01-13
- Earliest claimed: 2018-04-26
- Assignees: Agenus Inc.
- Applicants: Agenus Inc.
- Inventors: Mark Arthur FINDEIS; Benjamin Maxime MORIN; Bishnu JOSHI
- Web page: https://patentgrep.com/patent/US20220008527A1

## CPC

- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001114: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 39/12: Viral antigens
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61P 35/00: Antineoplastic agents
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/47: from mammals
- A61K 2039/5152: {Tumor cells}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/6043: {Heat shock proteins}
- A61K 2039/622: {non-covalent binding}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/70: containing domain for protein-protein interaction
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.

## Claims

### Claim at position 1

-126. (canceled)

### Claim 127

A composition comprising a complex of:
(a) a polypeptide comprising:
(i) an antigenic peptide comprising one or more major histocompatibility complex (MHC)-binding epitopes, and
(ii) an HSP-binding peptide comprising the amino acid sequence of SEQ ID NO: 6; and
(b) a purified stress protein.

### Claim 128 (depends on 127)

The composition of claim 127, wherein the amino acid sequence of the HSP-binding peptide consists of the amino acid sequence of SEQ ID NO: 6.

### Claim 129 (depends on 127)

The composition of claim 127, wherein the HSP-binding peptide is at the C-terminus of the polypeptide.

### Claim 130 (depends on 127)

The composition of claim 127, wherein the HSP-binding peptide is linked to the antigenic peptide via a peptide linker, optionally wherein the peptide linker comprises the amino acid sequence of SEQ ID NO: 13.

### Claim 131 (depends on 127)

The composition of claim 127, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 18.

### Claim 132 (depends on 127)

The composition of claim 127, wherein the polypeptide is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.

### Claim 133 (depends on 127)

The composition of claim 127, wherein the MHC-binding epitope is from a cancer cell and wherein the MHC-binding epitope comprises an amino acid mutation or a gene fusion mutation, optionally wherein
(a) the amino acid mutation is a substitution, deletion, or insertion mutation, and/or
(b) the amino acid mutation or gene fusion mutation is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 of the amino acid sequence of the antigenic peptide.

### Claim 134 (depends on 127)

The composition of claim 127, wherein the MHC-binding epitope is from a pathogenic microbe, optionally wherein the pathogenic microbe is a virus.

### Claim 135 (depends on 127)

The composition of claim 127, wherein the MHC-binding epitope comprises a modified amino acid residue, optionally wherein:
(a) the modified amino acid residue is a Tyr, Ser, Thr, Arg, Lys, or His that has been phosphorylated on a side chain hydroxyl or amine;
(b) the modified amino acid residue is a mimetic of a Tyr, Ser, Thr, Arg, Lys, or His amino acid that has been phosphorylated on a side chain hydroxyl or amine, optionally wherein the mimetic is a non-hydrolyzable analogue of a phosphorylated residue;
(c) the modified amino acid residue is an Asn that has been glycosylated on a side chain amide, a Ser or Thr that has been glycosylated on a side chain hydroxyl, a Lys or Arg that has been methylated on a side chain amino, a Lys that has been acetylated on a side chain amino, an N-terminal residue that has been acetylated on the α-amino, or a C-terminal residue that has been amidated on the α-carboxyl; and/or
(d) the modified amino acid residue is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 of the amino acid sequence of the antigenic peptide.

### Claim 136 (depends on 127)

The composition of claim 127, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-53.

### Claim 137 (depends on 127)

The composition of claim 127, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 54-69.

### Claim 138 (depends on 127)

The composition of claim 127, wherein:
(a) the stress protein is selected from the group consisting of Hsc70, Hsp70, Hsp90, Hsp110, Grp170, Gp96, Calreticulin, and a mutant or fusion protein thereof, optionally wherein the stress protein is human Hsc70;
(b) the stress protein is a recombinant protein;
(c) the composition comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different complexes, optionally wherein each of the different complexes comprises the same HSP-binding peptide and a different antigenic peptide, optionally wherein:
each one of the polypeptides comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 54-69;
(d) the amount of the stress protein in the composition is about 10 μg to 600 μg, optionally about 250 μg to 290 μg;
(e) the molar ratio of the polypeptide(s) to the stress protein is about 0.5:1 to 5:1, optionally about 1:1 to 2:1, such as 1:1, 1.25:1, or 1.5:1;
(f) the total amount of the polypeptide(s) and stress protein in the composition is about 10 μg to 600 μg, optionally about 300 μg;
(g) the composition further comprises an adjuvant, optionally wherein the adjuvant comprises:
a saponin or an immunostimulatory nucleic acid, optionally wherein the adjuvant comprises QS-21, optionally about 10 μg, 25 μg, or 50 μg of the QS-21, and/or
a TLR agonist, optionally a TLR4 agonist, TLR5 agonist, TLR7 agonist, TLR8 agonist, and/or TLR9 agonist;
(h) the composition comprises a pharmaceutically acceptable carrier or excipient; and/or
(i) the composition is in a unit dosage form.

### Claim 139 (depends on 127)

The composition of claim 127, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 18, and the stress protein is human Hsc70.

### Claim 140 (depends on 139)

The composition of claim 139, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 38-53.

### Claim 141 (depends on 139)

The composition of claim 139, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 54-69.

### Claim 142 (depends on 139)

The composition of claim 139, wherein:
(a) the composition comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 different complexes, optionally wherein each of the different complexes comprise the same HSP-binding peptide and a different antigenic peptide, optionally wherein:
each one of the polypeptides comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 54-69;
(b) the amount of the stress protein in the composition is about 10 μg to 600 μg, optionally about 250 μg to 290 μg;
(c) the molar ratio of the polypeptide(s) to the stress protein is about 0.5:1 to 5:1, optionally about 1:1 to 2:1, such as 1:1, 1.25:1, or 1.5:1;
(d) the total amount of the polypeptide(s) and stress protein in the composition is about 10 μg to 600 μg, optionally about 300 μg;
(e) the composition further comprises an adjuvant, optionally wherein the adjuvant comprises:
a saponin or an immunostimulatory nucleic acid, optionally wherein the adjuvant comprises QS-21, optionally about 10 μg, 25 μg, or 50 μg of the QS-21, and/or
a TLR agonist, optionally a TLR4 agonist, TLR5 agonist, TLR7 agonist, TLR8 agonist, and/or TLR9 agonist;
(f) the composition comprises a pharmaceutically acceptable carrier or excipient; and/or
(g) the composition is in a unit dosage form.

### Claim 143 (depends on 127)

A method of making the composition of claim 127, the method comprising mixing the polypeptide with the purified stress protein under suitable conditions such that the purified stress protein binds to the polypeptide.

### Claim 144 (depends on 139)

A method making the composition of claim 139, the method comprising mixing the polypeptide with the purified stress protein under suitable conditions such that the purified stress protein binds to the polypeptide.

### Claim 145 (depends on 127)

A method of inducing a cellular immune response to an antigenic peptide in a subject, the method comprising administering to the subject an effective amount of the composition of claim 127.

### Claim 146 (depends on 139)

A method of inducing a cellular immune response to an antigenic peptide in a subject, the method comprising administering to the subject an effective amount of the composition of claim 139.
